Pfizer to acquire Seagen


United States

Pfizer Inc has concluded its widely reported merger talks with Seagen Inc with a cash offer to acquire the company for $229 per share representing an enterprise value of about $43 billion. Located in Bothell, Washington, US, Seagen (formerly Seattle Genetics), is one of the first developers of antibody-drug conjugates (ADCs) which are monoclonal antibodies chemically linked to a drug and directed against cancer. The antibody binds to specific proteins on cancer cells and the linker enables the toxic drug payload to enter the cells and kill them.